Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.

by Jon T Giles, Erika Darrah, Sonye Danoff, Cheilonda Johnson, Felipe Andrade, Antony Rosen, Joan M Bathon
Published 2014-01-01

Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial

by Jon T. Giles, Pamela M. Rist, Katherine P. Liao, Ahmed Tawakol, Zahi A. Fayad, Venkatesh Mani, Nina P. Paynter, Paul M. Ridker, Robert J. Glynn, Fengxin Lu, Rachel Broderick, Meredith Murray, Kathleen M. M. Vanni, Daniel H. Solomon, Joan M. Bathon
Published 2021-06-01

What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak.

by Monica Mehta, Lawrence J Purpura, Thomas H McConville, Matthew J Neidell, Michaela R Anderson, Elana J Bernstein, Donald E Dietz, Justin Laracy, Shauna H Gunaratne, Emily Happy Miller, Jennifer Cheng, Jason Zucker, Shivang S Shah, Shaoli Chaudhuri, Christian A Gordillo, Shreena R Patel, Tai Wei Guo, Lara E Karaaslan, Ran Reshef, Benjamin A Miko, Joan M Bathon, Marcus R Pereira, Anne-Catrin Uhlemann, Michael T Yin, Magdalena E Sobieszczyk
Published 2021-01-01